Development of a case fatality prognostic score for HIV-associated histoplasmosis

Françoise, Ugo; Bourne-Watrin, M.; Epelboin, Loïc; Thorey, Camille; Demar, Magalie; Carod, Jean François; Djossou, Félix; Couppié, Pierre; Adenis, Antoine

doi:10.1016/j.ijid.2023.03.048

Cited by 1 publication

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Disseminated histoplasmosis is proteiform [ 56 ], and it may be severe, moderately severe or mild, with fuzzy boundaries between categories. The histoplasmosis cohort allowed us to determine prognostic factors for early death [ 57 ], with a recent update and prognostic score [ 58 ] to help determine what induction antifungal treatment should be given, itraconazole or liposomal amphotericin b; the cohort also allowed us to describe the various presentations [ 59 , 60 , 61 , 62 , 63 , 64 ], the proportion of severe forms and its relation with common clinical presentations [ 44 , 59 , 65 , 66 ].…”

Section: Resultsmentioning

confidence: 99%

Forty Years of HIV Research in French Guiana: Comprehend to Combat

Nacher,

Lucarelli,

Van-Melle

et al. 2024

Pathogens

Self Cite

View full text Add to dashboard Cite

The drivers of the HIV epidemic, the viruses, the opportunistic infections, the attitudes and the resources allocated to the fight against HIV/AIDS, vary substantially across countries. French Guiana, at the crossroads between Amazonian South America and the Caribbean, constitutes a singular context with poor populations and rich country health funding, which has allowed researchers to gather lots of information on the particulars of our epidemic. We aimed to focus on the little known story of forty years of HIV research in French Guiana and emphasize how local research intertwined with public health action has yielded continuous progress, despite the difficult social conditions of the affected population. We searched Web of Science and associated local experts who worked through much of the epidemic in selecting the most meaningful products of local research for clinical and public health outcomes in French Guiana. Research tools and facilities included, from 1991 onwards, the HIV hospital cohort and the HIV-histoplasmosis cohort. Ad hoc studies funded by the ANRS or the European Regional Development fund shed light on vulnerable groups. The cumulative impact of prospective routine collection and focused efforts has yielded a breadth of knowledge, allowing for informed decisions and the adaptation of prevention, testing and care in French Guiana. After this overview, we emphasize that the close integration of research and public health was crucial in adapting interventions to the singular context of French Guiana.

show abstract